DBV Technologies S.A. (PA:DBV) — Market Cap & Net Worth
Market Cap & Net Worth: DBV Technologies S.A. (DBV)
DBV Technologies S.A. (PA:DBV) has a market capitalization of $1.03 Billion (€882.73 Million) as of June 17, 2026. Listed on the PA stock exchange, this France-based company holds position #8962 globally and #144 in its home market, demonstrating a 11.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DBV Technologies S.A.'s stock price €3.19 by its total outstanding shares 295914379 (295.91 Million). Review DBV total debt and obligations to assess the company's total debt and financial obligations.
DBV Technologies S.A. Market Cap History: 2015 to 2026
DBV Technologies S.A.'s market capitalization history from 2015 to 2026. Data shows change from $22.98 Billion to $1.10 Billion (-24.05% CAGR).
Index Memberships
DBV Technologies S.A. is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$235.52 Billion | 0.44% | #54 of 119 |
|
CAC Small90
CACS
|
$36.94 Billion | 2.79% | #12 of 64 |
|
CAC All-Tradable
CACT
|
$2.89 Trillion | 0.04% | #112 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.89 Trillion | 0.04% | #112 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.89 Trillion | 0.04% | #112 of 179 |
|
CAC PME
CAPME
|
$40.75 Billion | 2.53% | #10 of 34 |
|
CAC Health Care
FRHC
|
$261.06 Billion | 0.40% | #11 of 36 |
Weight: DBV Technologies S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DBV Technologies S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DBV Technologies S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
207.47x
DBV Technologies S.A.'s market cap is 207.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $22.95 Billion | $10.40 Million | -$126.35 Million | 2207.65x | N/A |
| 2017 | $14.49 Billion | $13.63 Million | -$207.90 Million | 1063.30x | N/A |
| 2018 | $3.67 Billion | $16.64 Million | -$227.00 Million | 220.60x | N/A |
| 2019 | $6.79 Billion | $14.71 Million | -$195.20 Million | 461.73x | N/A |
| 2020 | $1.50 Billion | $11.28 Million | -$195.68 Million | 133.03x | N/A |
| 2021 | $1.06 Billion | $5.71 Million | -$97.81 Million | 185.40x | N/A |
| 2022 | $1.09 Billion | $4.80 Million | -$96.30 Million | 226.74x | N/A |
| 2023 | $639.67 Million | $15.73 Million | -$72.73 Million | 40.67x | N/A |
| 2024 | $217.95 Million | $4.15 Million | -$113.92 Million | 52.51x | N/A |
| 2025 | $1.17 Billion | $5.64 Million | -$152.94 Million | 207.47x | N/A |
Competitor Companies of DBV by Market Capitalization
Companies near DBV Technologies S.A. in the global market cap rankings as of June 17, 2026.
Key companies related to DBV Technologies S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
DBV Technologies S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, DBV Technologies S.A.'s market cap moved from $22.98 Billion to $ 1.10 Billion, with a yearly change of -24.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.10 Billion | -5.68% |
| 2025 | €1.17 Billion | +436.51% |
| 2024 | €217.95 Million | -65.93% |
| 2023 | €639.67 Million | -41.23% |
| 2022 | €1.09 Billion | +2.84% |
| 2021 | €1.06 Billion | -29.45% |
| 2020 | €1.50 Billion | -77.91% |
| 2019 | €6.79 Billion | +85.01% |
| 2018 | €3.67 Billion | -74.67% |
| 2017 | €14.49 Billion | -36.86% |
| 2016 | €22.95 Billion | -0.12% |
| 2015 | €22.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of DBV Technologies S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more